Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bean, A. J.
Right arrow Articles by Chang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bean, A. J.
Right arrow Articles by Chang, Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

J Biol Chem, Vol. 275, Issue 20, 15271-15278, May 19, 2000


Hrs-2 Regulates Receptor-mediated Endocytosis via Interactions with Eps15*

Andrew J. BeanDagger , Svend Davanger§, Marian F. Chou, Brenda Gerhardt, Susan Tsujimoto, and YuChieh Chang

From the Department of Neurobiology and Anatomy, and The W. M. Keck Center for the Neurobiology of Learning and Memory, University of Texas Medical School, Houston, Texas 77030 and the § Department of Cell Biology and Anatomy, University of Bergen, Bergen 5009, Norway

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hrs-2, via interactions with SNAP-25, plays a regulatory role on the exocytic machinery. We now show that Hrs-2 physically interacts with Eps15, a protein required for receptor-mediated endocytosis. The Hrs-2/Eps15 interaction is calcium dependent, inhibited by SNAP-25 and alpha -adaptin, and results in the inhibition of receptor-mediated endocytosis. Immunoelectron microscopy reveals Hrs-2 localization on the limiting membrane of multivesicular bodies, organelles in the endosomal pathway. These data show that Hrs-2 regulates endocytosis, delineate a biochemical pathway (Hrs-2-Eps15-AP2) in which Hrs-2 functions, and suggest that Hrs-2 acts to provide communication between endo- and exocytic processes.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Initial attempts to understand the molecular basis of exocytosis involved the characterization of proteins present on synaptic vesicles and on the presynaptic plasma membrane (1-3). These studies revealed a series of protein-protein interactions that have been suggested to mediate events leading to the fusion of vesicles with the plasma membrane (1-4). SNAP-251 is associated with the plasma membrane and binds to both syntaxin (found on the plasma membrane) and VAMP (found on the vesicle) (4-7). Through these interactions SNAP-25 is a critical component of a protein complex (7 S) that is proposed to be necessary for fusion of synaptic vesicles with the plasma membrane (4, 6-9).

Hrs-2 is an ATPase that physically associates with SNAP-25 in a calcium-regulated manner (10). Hrs-2 binds to SNAP-25 through its second coiled-coil domain and does not directly interact with either syntaxin or VAMP (11). When Hrs-2 is bound to the complex of SNAP-25 and syntaxin, VAMP binding to SNAP-25 is inhibited, reducing the amount of 7 S complex formed (11). Thus, Hrs-2, via interaction with SNAP-25, may play a negative regulatory role on the exocytic machinery that is alleviated when calcium concentrations are elevated, dissociating Hrs-2 from the Hrs-2·SNAP-25·syntaxin complex and allowing VAMP to bind to SNAP-25/syntaxin.

Ultrastructural and physiological experiments have identified at least two endocytic pathways: a rapid clathrin-independent pathway, and a slower clathrin-dependent pathway (12-21). Clathrin triskelia form cages that capture vesicle membrane for retrieval during the endocytic process (14, 22, 23). Clathrin and its adapter proteins (AP2 and AP180 are recruited to the plasma membrane and link clathrin to the membrane) along with other binding partners (e.g. dynamin and amphiphysin) appear to be involved in early events in the endocytic pathway related to vesicle budding and maturation (14, 22-29). Other proteins necessary for endocytosis have been found in genetic screens as well as by using biochemical methods. Eps15 is the prototypical member of a family of proteins containing EH motifs that bind to NPF domains in target proteins (30-37). Eps15 contains three amino-terminal EH domains, a central coiled-coil region, and 15 COOH-terminal DPF repeats (32, 33). Eps15 is localized to components of the endocytic pathway (38) and has been shown to be essential for receptor-mediated endocytosis through interactions with alpha -adaptin (35, 39). The yeast homolog of Eps15, Pan1p, is an EH domain-containing protein found in Saccharomyces cerevisiae that is required for endocytosis (31, 40). Additionally, Pan1p binds to another EH-containing protein, END3p, as well as the yeast homolog of AP180, and has genetic interactions with synaptojanin and a ubiquitin-protein ligase (31, 40).

Exocytosis and endocytosis are closely linked and temporally coordinated during the vesicle cycle. These two distinct events must be regulated precisely such that they occur sequentially in order to maintain the fidelity of vesicle-mediated secretion and cellular architecture. However, the molecular mechanisms that coordinate these events remain elusive. The protein machinery involved in endocytosis and exocytosis is a likely substrate for their interaction. We have found that Hrs-2, a protein implicated in regulation of the formation of the SNAP-25·syntaxin·VAMP complex, interacts with Eps15, a protein necessary for clathrin-mediated endocytosis. The interaction of Hrs-2 with Eps15 is calcium dependent, is inhibited by SNAP-25 and alpha -adaptin, and results in the inhibition of receptor-mediated endocytosis. Moreover, the inhibition of endocytosis produced by expression of Hrs-2 is rescued by coexpression of alpha -adaptin. These data show that Hrs-2 has a regulatory role in endocytosis, delineate a biochemical pathway (Hrs-2-Eps15-AP2) in which Hrs-2 functions, and suggest a mechanism by which exocytosis and endocytosis are linked.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Two-hybrid Assay-- Full-length rat Hrs-2 was subcloned into the pGBT vector and used to screen a human brain cDNA library inserted downstream of the GAL4 activation domain in the pGAD10 vector (CLONTECH). Yeast strains (SFY526, HF7c) used herein have been previously characterized (S. Fields, CLONTECH). All constructions were verified by sequencing (Sequenase). 3.06 × 106 independent clones were screened by sequential transformation with pGBT/Hrs-2 and pGAD/library followed by plating on agar containing yeast nitrogen base (6.7 g/liter, Difco), dextrose (2%), and an amino acid mixture lacking histidine, leucine, tryptophan, and uracil and stored at 30 °C in the dark. Five-12 days after plating, large colonies (>3 mm diameter, n = 190) were replica plated onto new plates and beta -galactosidase activity was assessed on filter lifts. Single colonies from clones that turned blue within 1 h (n = 40) were grown overnight in SD medium lacking leucine, tryptophan, and histidine and DNA was extracted. DNA was electroporated into HB101 Escherichia coli cells, and DNA was isolated from single colonies. After restriction digests confirmed the presence of the activation domain plasmid, multiple co-transformations were performed with the candidate DNA and the pGBT9/Hrs-2, as well as pGBT9/p53. Clones that reacted positively for beta -galactosidase activity with the pGBT9/Hrs-2 but not either by themselves or with the control plasmids containing the binding domain alone or the binding domain fused to the tumor supressor gene p53, were considered for further study (n = 36). Sequencing revealed a single clone whose sequence was identical to SNAP-25b and a single clone identical to human Eps15 (amino acids 416-858). Other clones remain to be analyzed.

Immunoprecipitation-- Hrs-2 monoclonal antibody or purified mouse IgG was cross-linked to Protein A-agarose using dimethylpimelimidate. Rat brain postnuclear supernatant was precleared with protein A-agarose and incubated with either anti-Hrs-2 or mouse IgG overnight at 4 °C. Following four washes with PBS-T, samples were boiled in sample buffer and separated using SDS-PAGE. Proteins were transferred to membranes that were probed with Eps15 (Santa Cruz Biotech) or Hrs-2 (41) antibodies.

Production of Recombinant Proteins-- Full-length Hrs-2 was subcloned into Hta baculovirus vector (Life Technologies, Inc.), and Hrs-2 virus was produced according to the manufacturer's protocol. Hrs-2 protein was produced by infecting a 500-ml culture of Sf21 cells at a multiplicity of infection of 0.1. Post-infection (72-96 h), cells were harvested by centrifugation, and pellets were frozen. Proteins were extracted by incubation (60 min at 4 °C) with 5% betaine in 10 mM Tris, pH 7.5, 1 mM EGTA, 1 mM EDTA, and a mixture of protease inhibitors including aprotinin, pepstatin, and phenylmethylsulfonyl fluoride, affinity isolated using Ni-NTA-agarose (Qiagen), and eluted from the resin when necessary, using 250 mM imidazole. Hrs-2 truncations were produced as described (11). GFP fusion proteins were produced in pEGFP (CLONTECH) by direct transfer from the GST vector. Hrs-2Delta eps was produced by partial digestion of pEGFP-Hrs-2 with PstI removing amino acids 258-484. Using the two-hybrid technique we have observed that the Hrs-2Delta eps protein does not bind to Eps15 although it does bind to SNAP-25 and full-length Hrs-2 (data not shown).

SNAP-25 was subcloned into pGEX-KG and grown at 37 °C in the AB1899 strain of E. coli. Full-length GST-Eps15 was a kind gift of A. E. Salcini and P. DiFiore, while deletion constructs of Eps15 were a kind gift of A. Benmerah and N. Cerf-Bensussan. All constructs were grown in BL21 cells at 37 °C. After reaching mid-log phase, isopropyl-1-thio-beta -D-galactosidase (300 µM) was added, and cells were incubated for an additional 3 h. Cells were harvested by centrifugation, lysed in a French Press, and protein was affinity isolated using glutathione-agarose.

In Vitro Binding-- Eps15/GST (0.3 µM) bound to glutathione beads was incubated with the indicated amount of recombinant Hrs-2 protein for 60 min at 4 °C in either: 10 mM Hepes-KOH, pH 7.5, 140 mM KoAc, 1 mM MgCl2, 0.1 mM EGTA, 0.1% gelatin, 0.05% Tween 20 or the same buffer containing either 2 mM EGTA and various concentrations of Ca2+, Ba2+, or Sr2+. Beads were washed 3 times with PBS-T, and the proteins remaining on the beads were solubilized in 15 µl of sample buffer. Samples were separated using SDS-polyacrylamide gels and transferred to nitrocellulose. Western blotting was performed using anti-Hrs-2 antibodies followed by 125I-labeled secondary antibody and quantitated by phosphorimaging. The EC50 is defined as half-maximal binding of each soluble protein based on optical density obtained by phosphorimaging (Molecular Dynamics model 300A).

For saturation binding, various concentrations of Hrs-2 were incubated (4 °C for 60 min) with glutathione-agarose beads containing either glutathione S-transferase or Eps15. To determine interacting domains, various Hrs-2 or Eps15 fragments were purified and incubated (4 °C for 60 min) with either Eps15 or Hrs-2, respectively. For complex formation studies Hrs-2 bound to Ni-agarose was incubated with Eps15 alone or Eps15 and various concentrations of SNAP-25 at 4 °C for 60 min. To determine whether Ca2+ had an effect on Hrs-2/Eps15 interactions, single concentrations of Hrs-2 were incubated with Eps15 bound to glutathione-agarose (4 °C for 60 min) in the presence of various concentrations of free Ca2+ (buffered with 2 mM EGTA and calculated using WebMaxCalc version 1.1). Free Ba2+ or Sr2+ (0.5 mM) were used to examine selectivity. To examine the effect of alpha -adaptin on Hrs-2/Eps15 binding, Eps15 was immobilized on glutathione-agarose and then incubated with alpha -adaptin bacterial lysate. The Eps15-agarose, with or without with alpha -adaptin, was then incubated with increasing concentrations of Hrs-2. Following binding incubations, reactions were washed 3 times with PBS containing 0.05% Tween 20, and SDS sample buffer was added to the beads. Proteins bound to the beads were separated by SDS-PAGE and subjected to immunoblot analysis using anti-Hrs-2 antibodies and either horseradish peroxidase- or 125I-labeled secondary antisera.

Immunohistochemistry-- For electron microscopic immunohistochemical localization, rats were perfused with 3% paraformaldehyde, 0.1% glutaraldehyde, 0.2% picric acid in 0.1 M phosphate buffer. Brains were post-fixed in situ and sectioned on a vibratome. Tissues were embedded in Lowecryl and thin sectioned. Embedded tissues were incubated with Hrs-2 antibody (10) (1:200), anti-rabbit secondary antibody conjugated to 1.4 nm gold particles (nanogold 2004, Nanoprobes, Stony Brook, NY), and silver intensified (Nanoprobes). Cells were examined on an electron microscope (Jeol) and photographed.

Receptor-mediated Endocytosis-- HeLa cells were maintained in Dulbecco's modified Eagle's medium with 10% fetal calf serum and penicillin/streptomycin. Cells were plated onto coverslips and transiently transfected (Qiagen, effectene transfection reagent) with pEGFP, pEGFP-Hrs-2, pEGFP-Hrs-2Delta Eps15, pEGFP-Hrs-2 fragments, pCDNA3-alpha -adaptin or pEGFP-Hrs-2+pCDNA3-alpha -adaptin 24 h prior to endocytosis experiments. To examine receptor-mediated endocytosis, transfected HeLa cells were serum starved for 1 h prior to incubation (10 min at 4 °C followed by 3 washes with media) with Alexa 594-conjugated transferrin. After the chamber temperature was heated back to 37 °C, images were acquired on a Zeiss Aviovert microscope with a Hamamatsu ORCA CCD camera between 5 and 20 min post-warming. Experiments using pCDNA3-alpha -adaptin were performed identically except that after the unbound transferrin was washed, the cells were fixed in 4% paraformaldehyde for 10 min and then washed three times in PBS. The alpha -adaptin was visualized using a monoclonal antibody (Sigma) and cy-5 secondary antibody on a Bio-Rad 1024 confocal microscope. Image analysis was performed on a Macintosh computer using the public domain NIH Image program (version 1.62) and consisted of outlining cells and computing the area and mean gray value of the region of interest. This computation was performed after the threshold was set automatically based on an analysis of the histogram of the region of interest. Data are presented in units of integrated density (area of the cells × mean pixel volume) and are normalized to untransfected cells for graphical representation. The number of cells analyzed from each group is listed in the figure legend. Differences between groups were analyzed using ANOVA with post-hoc Dunnetts test.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Hrs-2 Interacts with Eps15-- Using full-length Hrs-2 as bait in a two-hybrid screen, we recovered a cDNA clone identical to amino acids 416-858 of human Eps15. The interaction appeared specific as it was not observed using either p53 or GAL4 as bait (data not shown). To confirm the two-hybrid result we obtained the rat Eps15 clone, produced the recombinant protein, and performed binding assays using purified Hrs-2 and Eps15 (Fig. 1A). Hrs-2 binding to immobilized Eps15 approached saturation with an apparent EC50 for binding of ~1.8 µM. These data suggest that Hrs-2 interacts with Eps15 directly in the absence of other protein components.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 1.   Characterization of Hrs-2 interaction with Eps15. A, recombinant Hrs-2 binding to immobilized Eps15. Eps15 (0.3 µM) was immobilized on glutathione beads and incubated with increasing concentrations of Hrs-2. Hrs-2 did not bind to GST bound to glutathione-agarose (see graph). The EC50 (affinity is reported as the 50% effective concentration (EC50), the concentration of protein at which half-maximal binding occurs, instead of Kd, since the washing phase of these in vitro binding assays is conducted under non-equilibrium conditions) of Hrs-2 for immobilized Eps15 is 1.8 µM, and the stoichiometry is 0.1-0.4:1 (Eps15:Hrs-2) depending on which protein is immobilized. B, coimmunoprecipitation of Eps15 and Hrs-2. Brain post-nuclear supernatant (PNS) containing Eps15 and Hrs-2 (lane 1) was incubated with anti-Hrs-2 antibodies (lane 2) or purified mouse IgG (lane 3). The co-precipitation of Eps15 and Hrs-2 from brain confirms the interaction observed using the two-hybrid system and binding of recombinant fusion proteins (in A). C, five GST-Hrs-2 fusion proteins encompassing residues 1-478 (A), 1-449 (B), 216-449 (C), 450-478 (D), and 515-562 (E, depicted in the schematic diagram, top) were generated by bacterial expression, immobilized on glutathione-agarose beads, and assayed for binding interactions with full-length Eps15. Eps15 binds to Hrs-2 truncation mutants that contain the region between the FYVE finger and the first coiled-coil domain (216-449, lanes A-C). Neither of the two coiled-coil regions (lanes D and E) were able to bind Eps15. These data suggest that the region between the FYVE finger and the first coiled-coil domain of Hrs-2 is necessary and sufficient to bind Eps15. D, five GST-Eps15 fusion proteins encompassing residues 1-320 (DI), 320-529 (DII), 529-896 (DIII), 529-763 (DIII0), and 529-618 (DIII3) (depicted in schematic diagram, top) were expressed in BL21 cells, immobilized on glutathione-agarose beads, and assayed for binding interactions with full-length Hrs-2. Hrs-2 binds to both DII and DIII but not to DI. Truncation mutants of DIII were used to determine that Hrs-2 binds in the region required for alpha -adaptin binding and not in other regions of Eps15. Thus, either the coiled-coil region (DII) or the AP2-binding domain of Eps15 is sufficient for Hrs-2 binding.

Eps15 from brain postnuclear supernatant was found to coimmunoprecipitate with Hrs-2 (Fig. 1B). Thus, while Eps15 was bound to protein A-Sepharose to which Hrs-2 antibody had been cross-linked (lane 2), Eps15 was not detected on protein A-Sepharose containing a control antibody, mouse IgG (lane 3). These data support the two-hybrid data and confirm that Hrs-2 can interact with Eps15 from brain.

We used truncated forms of the recombinant proteins to determine the domains of Hrs-2 and Eps15 that mediate the interaction between these molecules. To determine the domain of Hrs-2 that binds to Eps15, we constructed a set of GST fusion proteins containing regions of Hrs-2 predicted to form structural motifs (Fig. 1C, top). These truncation mutants were expressed, bound to glutathione-agarose beads, and then examined for interaction with full-length soluble Eps15 during an in vitro binding assay. As shown in Fig. 1C (bottom), Eps15 bound to Hrs-2 truncations that contained the region between the FYVE zinc finger region and the first coiled-coil domain, and not to GST beads alone or to either of the coiled-coil regions. Since Eps15 was able to bind to the Hrs-2 truncation containing amino acids 216-449, we conclude that this region of Hrs-2 is both necessary and sufficient for the binding of Eps15.

In a similar manner, we determined the domain of Eps15 that binds to Hrs-2 (Fig. 1D). GST fusion proteins containing regions of Eps15 were expressed, immobilized on glutathione-agarose, and then assayed for interaction with full-length Hrs-2. Hrs-2 bound to both the coiled-coil domain and the carboxyl-terminal domain of Eps15 that contains NPF repeats (Fig. 1D). Moreover, the region in the carboxyl-terminal domain necessary for Hrs-2 binding was delineated using additional deletion constructs of that region and found to correspond to the region required for alpha -adaptin binding to Eps15 (Fig. 1D). The amino-terminal EH domain construct was unable to interact with Hrs-2. Thus, we conclude that Eps15 contains two domains capable of interaction with Hrs-2, the coiled-coil motif, as well as the alpha -adaptin binding region in the COOH-terminal domain.

The Interaction of Hrs-2 with Eps15 Is Dependent on Calcium-- Since Hrs-2 is known to have calcium-sensitive interactions with SNAP-25, we examined whether the interaction with Eps15 is altered by calcium. Recombinant Eps15 was immobilized, and a single concentration of Hrs-2 was added in the presence of increasing free Ca2+. As the concentration of Ca2+ was increased, less Hrs-2 bound to Eps15 (Fig. 2). The half-maximal inhibition of Hrs-2 binding produced by Ca2+ was ~100 nM. Ba2+ and Sr2+ (0.5 mM concentrations) did not effect the binding of Hrs-2 to Eps15 (data not shown). These data suggest that Ca2+ regulates the ability of Hrs-2 and Eps15 to interact.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of Ca2+ and SNAP-25 on the interaction of Hrs-2 with Eps15. Ca2+ inhibits Hrs-2 binding to Eps15. A single concentration of Hrs-2 (0.6 µM) was incubated in the presence of increasing concentrations of free Ca2+ and GST-Eps15 (0.22 µM) immobilized on glutathione-agarose. As the Ca2+ concentration was increased the amount of Hrs-2 bound to Eps15 decreased. The half-maximal inhibition was approximately 100 nM. This concentration approaches the resting level of Ca2+ in the cell.

Eps15 and SNAP-25 Compete for Hrs-2 Binding-- The calcium concentration necessary for half-maximal inhibition of Hrs-2/Eps15 binding is ~1000 × lower than that needed to inhibit Hrs-2/SNAP-25 binding, suggesting that Eps15 and SNAP-25 do not interact with Hrs-2 simultaneously. Additionally, since SNAP-25 is involved in regulation of the exocytic machinery and Eps15 in the endocytic machinery, it seems unlikely that they would bind to Hrs-2 simultaneously. To examine whether SNAP-25 and Eps15 interact with Hrs-2 simultaneously, we incubated immobilized Hrs-2 with Eps15 and increasing concentrations of SNAP-25 (Fig. 3). As the concentration of SNAP-25 increased, less Eps15 bound to Hrs-2. At 3 µM SNAP-25, Eps15 binding was reduced by 90% indicating that while SNAP-25 and Eps15 can both bind to Hrs-2, SNAP-25, and Eps15 do not bind to Hrs-2 simultaneously.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 3.   SNAP-25 inhibits the interaction of Hrs-2 with Eps15. A constant concentration of Eps15 (0.1 µM) was incubated with increasing concentrations of SNAP-25 and Hrs-2 (0.2 µM) immobilized on nickel-agarose. As the concentration of SNAP-25 was increased the amount of Eps15 bound decreased (lanes 1-5). Pixel values for Eps15 were 22,334, 17,606, 7807, 5888, and 2016, while pixel values for SNAP-25 were 1444, 16,071, 11,695, 26,251, 22,472. A Ponceau stain of the blot (Hrs-2) shows equal loading of Hrs-2 coupled to agarose.

Hrs-2 and Eps15 Are Present on Endocytic Structures-- The demonstration of a direct interaction between Hrs-2 and Eps15 suggests that Hrs-2 may play a role in the endocytic machinery. Eps15 is localized to components of the endocytic pathway (38, 42). Electron microscopic studies have localized Eps15 at the rim of budding vesicles (42), although biochemical studies indicate that Eps15 is present throughout the endocytic pathway and undergoes cycles of association and dissociation with membranes in multiple endocytic compartments (38). Komada et al. (43) have reported that a homolog of Hrs-2, Hrs, is localized on early endosomes in HeLa cells that are overexpressing HA-tagged hrs. To understand where in the endocytic pathway Hrs-2 and Eps15 may interact, we examined the ultrastructural localization of Hrs-2 in neurons. As shown in Fig. 4, gold particles were localized on the limiting membrane of MVBs (Fig. 4, A-C). Additional Hrs-2 immunoreactivity was found intracellularly although it did not appear to be associated with any organelle or membrane and is therefore assumed to be cytosolic. Differential centrifugation reveals that approximately 75% of Hrs-2 is cytosolic,2 and we observed the majority of labeling on MVBs, suggesting that we cannot detect all of the intracellular Hrs-2 with our technique. The presence of Hrs-2 on limiting membranes of MVBs suggests an anatomical substrate for the interaction of Hrs-2 with Eps15 on this organelle.


View larger version (176K):
[in this window]
[in a new window]
 
Fig. 4.   Ultrastructural localization of Hrs-2 in neurons. Immunogold labeling of cerebellar neurons using an Hrs-2 antibody that was detected using silver-intensified gold and revealed labeling associated with MVBs (A, B, and C) along with some cytoplasmic and endosomal labeling (A). Scale bar = 110 nm in A, and 220 nm in B and C.

Eps15 Mediates the Hrs-2-induced Inhibition of Receptor-mediated Endocytosis-- To examine whether Hrs-2 and Eps15 are coupled functionally in the endocytic pathway we studied the effect of Hrs-2 on the uptake of fluorescently labeled transferrin in HeLa cells (Fig. 5). The uptake of transferrin is dependent on Eps15 (35, 39, 44). HeLa cells overexpressing GFP-tagged Hrs-2 displayed markedly reduced transferrin uptake compared with untransfected cells (Fig. 5, A versus B). Quantification of these data revealed a significant inhibition of transferrin uptake in cells overexpressing Hrs-2 (Fig. 5, bar graph). We expressed a GFP-Hrs-2 construct lacking the Eps15-binding domain (GFP-Hrs-2Delta eps) in HeLa cells. In contrast to the wild type Hrs-2 construct, the GFP-Hrs-2Delta eps construct was cytosolic in localization, suggesting the need for the Eps15 binding region of Hrs-2 for punctate localization (Fig. 5C), and transferrin uptake in cells expressing GFP-Hrs-2Delta eps was not significantly different from untransfected cells (Fig. 5D). We next overexpressed a portion of Hrs-2 containing only the Eps15-binding region, Hrs-2(216-449). Hrs-2(216-449) was punctate in localization and significantly inhibited transferrin uptake (Fig. 5, E and F). Expression of the coiled-coil region of Hrs-2 necessary for SNAP-25 interaction (Hrs-2 cc2) did not significantly affect transferrin uptake (Fig. 5, G and H). These data suggest that Hrs-2 can inhibit endocytosis and that its interaction with Eps15 is necessary for this function.


View larger version (25K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of Hrs-2, Hrs-2Delta eps, Hrs-2(216-449), and Hrs-2 cc2 on receptor-mediated endocytosis in HeLa cells. GFP tagged Hrs-2, Hrs-2Delta eps, Hrs-2(216-449), or Hrs-2 cc2 were transfected into HeLa cells, and the uptake of Alexa594-labeled transferrin was examined. A, wild-type GFP-Hrs-2 induced the appearance of large intracellular compartments, and cells expressing GFP-Hrs-2 (n = 18) were deficient in the uptake of transferrin compared with untransfected cells (B, bar graph). Overexpression of GFP-hrs2Delta eps (n = 18) resulted in cytosolic distribution of the protein (C) and transferrin uptake that was not significantly different than untransfected cells (D, bar graph). Overexpression of Hrs-2(216-449) (n = 18) resulted in a punctate localization (E) and transferrin uptake that was significantly different from untransfected cells (F, bar graph). Expression of Hrs-2 cc2 (n = 15) resulted in a puntate localization (G) but did not significantly inhibit transferrin uptake (H, bar graph). * denotes significance using ANOVA with multiple comparisons p <=  0.007.

Hrs-2 Inhibits Receptor-mediated Endocytosis by Competing with alpha -Adaptin for Eps15-- Hrs-2 binds to Eps15 through two domains, one of which is also necessary for alpha -adaptin binding (Fig. 1). Since Eps15 regulates endocytosis through an interaction with alpha -adaptin, and Hrs-2 can regulate this process, we examined whether Hrs-2 regulates endocytosis by altering the Eps15/alpha -adaptin interaction. Immobilized Eps15 was incubated with increasing concentrations of Hrs-2 in the presence and absence of alpha -adaptin (Fig. 6A). In the absence of alpha -adaptin, Hrs-2 bound to Eps15 as we had observed in Fig. 1. In the presence of alpha -adaptin the binding of Hrs-2 to Eps15 was markedly reduced (Fig. 6A, lanes 2-5 compared with 6-9). These data suggest that Hrs-2 and alpha -adaptin compete for binding to Eps15.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 6.   alpha -Adaptin competes with Hrs-2 for binding to Eps15 and suppresses Hrs-2 inhibition of receptor-mediated endocytosis. Immobilized Eps15 was incubated with increasing concentrations of Hrs-2 in the absence and presence of alpha -adaptin (A). In the absence of alpha -adaptin (lanes 2-5), Hrs-2 bound to Eps15 as we had observed in Fig. 1. In the presence of alpha -adaptin (lanes 6-9), the binding of Hrs-2 to Eps15 was reduced (A). The concentration of immobilized Eps15 was held constant at 0.3 µM. Lane 1 contains GST (0.6 µM) as a negative control. The Ponceau-stained blot is shown as a loading control. Hrs-2 concentrations and integrated density values (×1000) were: lane 1, 4 µM, 1.73; lane 2, 1 µM, 2.08; lane 3, 2 µM, 7.58; lane 4, 3 µM, 9.62; lane 5, 4 µM, 18.07; lane 6, 1 µM, 2.95; lane 7, 2 µM, 2.11; lane 8, 3 µM, 2.56; lane 9, 4 µM, 2.51. These data suggest that Hrs-2 and alpha -adaptin likely do not bind to Eps15 simultaneously. B, expression of Hrs-2 (n = 15) significantly inhibited, while alpha -adaptin (n = 20) had no significant effect on transferrin uptake (B). Transferrin uptake in cells coexpressing alpha -adaptin and Hrs-2 (n = 15) was not significantly different than that found in untransfected cells. * denotes significance using ANOVA with multiple comparisons p <=  0.005.

If Hrs-2 inhibits endocytosis by competition with alpha -adaptin for Eps15 binding, then expression of alpha -adaptin may rescue the inhibition of endocytosis produced by expression of Hrs-2. Expression of Hrs-2 significantly inhibited, while alpha -adaptin had no significant effect on transferrin uptake (Fig. 6B). However, transferrin uptake was not significantly different than control in the cells coexpressing alpha -adaptin and Hrs-2 (Fig. 6B). Since Hrs-2 apparently competes with alpha -adaptin for Eps15 binding, these data suggest a mechanism in which Hrs-2 regulates endocytosis by binding to Eps15, reducing its availability for alpha -adaptin binding.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Using the two-hybrid approach we have found that Hrs-2 associates with Eps15. We have confirmed a direct physical interaction using recombinant fusion proteins and coimmunoprecipitation. Additionally, we have shown that SNAP-25 competes with Eps15 for binding to recombinant Hrs-2. The binding of the recombinant Hrs-2 protein to Eps15 is calcium-dependent as the addition of calcium inhibits the Hrs-2/Eps15 interaction. Furthermore, overexpression of full-length Hrs-2 or only the region necessary for Eps15 binding, but not a mutant Hrs-2 lacking the Eps15-binding domain, inhibits the endocytosis of transferrin in HeLa cells. Moreover, both Eps15 and Hrs-2 are localized to components of the endocytic pathway. Thus, Hrs-2 is involved in endocytic processes through interactions with Eps15. Since Hrs-2 is involved in regulation of exocytic complex assembly and is unable to interact with SNAP-25 and Eps15 simultaneously, these data suggest that Hrs-2 may provide communication between endo- and exocytic processes by regulated interactions with the molecular machinery underlying both functions.

The in vitro binding of recombinant Hrs-2 and Eps15 demonstrates a direct interaction in the absence of other protein components. The EC50 of the Hrs-2/Eps15 interaction is approximately 1.8 µM. Thus, the interaction of Hrs-2 with Eps15 in vitro is of lower apparent affinity than that of the Hrs-2 with SNAP-25. This may reflect a more transient in vivo Hrs-2/Eps15 interaction or may be related to the ability of SNAP-25 to displace Eps15 from Hrs-2 (see below).

The binding site of Eps15 on Hrs-2 is in a region between the FYVE finger and the first coiled-coil domain, a different region from that involved in SNAP-25 binding (11). The inhibition of Eps15 binding to Hrs-2 by SNAP-25 was therefore unexpected based on the difference in their binding site localization. Conformational changes due to SNAP-25 binding may result in an altered affinity of Hrs-2 for Eps15. The ability of SNAP-25 to inhibit Eps15 binding to Hrs-2 suggests that Hrs-2 may toggle between SNAP-25 and Eps15, perhaps based on local calcium concentrations (see below). Hrs-2 binds to two distinct regions of Eps15, the coiled-coil and the alpha -adaptin-binding region in the COOH-terminal of Eps15. The coiled coil region of Eps15 in responsible for homoligomerization (45) which has been shown to result in increased affinity of Eps15 for alpha -adaptin (46). These data suggest that the Hrs-2/Eps15 interaction may alter the oligomeric state of Eps15 and/or its association with alpha -adaptin, or that Hrs-2 may not interact with the fraction of Eps15 that is in a complex with alpha -adaptin. Since the Eps15/alpha -adaptin association is required for endocytosis (35, 39), the inhibition of this interaction by Hrs-2 would be expected to inhibit endocytosis and may underlie the inhibition of endocytosis produced by overexpression of Hrs-2 (see below).

Calcium inhibits the binding of Eps15 to Hrs-2. Secondary structure predictions reveal that Hrs-2 may form multiple helix-loop-helix structures and could coordinate divalent cations in its dual zinc finger region (10). Additionally, Eps15 may form helix-loop-helix structures and has been suggested to bind calcium (33). Neither Hrs-2 nor Eps15 have been formally shown to bind calcium. However, both proteins have potential divalent cation binding sites and are altered in their ability to interact with other proteins when calcium is present. The half-maximal calcium concentration for the inhibition of Hrs-2 Eps15 binding is approximately 100 nM, which approaches the resting level of calcium in the cell. Thus, either compartmentalization within the cell produces low calcium concentrations near endocytic structures or, perhaps more likely, the binding of Hrs-2 to Eps15 is finely regulated by very small alterations in intracellular calcium. There is a 1000-fold difference in the calcium sensitivity of the binding of Hrs-2 to Eps15 compared with the Hrs-2/SNAP-25 interaction. The mechanism of the differential sensitivity to calcium may involve differences in Hrs-2, SNAP-25, and/or Eps15 protein conformation due to the presence of calcium. Alternatively, calcium may alter the oligomeric state of Hrs-2 or Eps15.

Eps15 has been shown to be associated with components of the endocytic pathway by biochemical fractionation as well as electron microscopy (38, 42). Initially, Eps15 was suggested to be present only on the edges of membrane invaginations (42), although recent data suggest that it is associated with both early and late endosomes during epidermal growth factor receptor-stimulated endocytosis (38). We have observed Hrs-2 immunoreactivity on the limiting membrane of MVBs in nerve terminals in the brain. MVBs are a sorting organelle in the late endocytic pathway that function to separate proteins destined for degradation in the lysosome from those that recycle back to the Golgi (e.g. mannose 6-phosphate receptor) or to the plasma membrane (e.g. transferrin receptor) (47-50). Examination of wild type and kinase mutant epidermal growth factor receptor internalization suggests that mutant receptors are found on the MVB limiting membrane and are recycled back to the plasma membrane, while wild type receptors are found in luminal MVB vesicles and are degraded (48). We have not observed labeling for Hrs-2 on the internal vesicles of MVBs. These data suggest that Hrs-2 is involved in functions related to the trafficking of the MVBs themselves or to sorting in the MVB compartment.

In addition to its localization on endocytic structures, we expected to find Hrs-2 immunoreactivity on the plasma membrane or components of the exocytic pathway due to its interaction with SNAP-25. We have observed Hrs-2 immunoreactivity in nerve terminals and cell bodies that appeared not to be associated with membranous structures. Negative immunohistochemical data is difficult to interpret. It is possible that the binding of Hrs-2 to SNAP-25, as would likely occur on the plasma membrane, masks the epitope for our antibody resulting in a lack of labeling on this structure.

Expression of Hrs-2 or the region of Hrs-2 that is necessary for Eps15 binding (Hrs-2(216-449)) inhibits receptor-mediated endocytosis in HeLa cells. Hrs-2 lacking the Eps15-binding domain (Hrs-2Delta Eps15) or the Hrs-2 fragment (cc2) necessary for binding to SNAP-25 do not inhibit receptor-mediated endocytosis in HeLa cells. Thus, the mechanism by which Hrs-2 inhibits endocytosis involves Eps15 or its downstream effectors. Eps15 is known to bind to alpha -adaptin, an interaction required for receptor-mediated endocytosis (35, 39). We observed that Hrs-2 and alpha -adaptin compete for binding to Eps15 and that the Hrs-2-induced disruption of endocytosis is rescued by alpha -adaptin. The interaction of Hrs-2 with Eps15 might be an upstream event (prior to Eps15/alpha -adaptin binding) in the biochemical pathway that results in endocytosis and Hrs-2 would therefore be well positioned to act on this process in a regulatory manner. Local calcium concentration, lipid binding, or post-translational modifications may regulate Hrs-2 itself. Endocytosis is an energy-dependent process with at least two ATP-dependent steps (51). Thus, the ATPase activity of Hrs-2 may provide for ATP-dependent alterations in protein conformation or protein complex assembly/disassembly that are necessary for endocytosis. The molecular mechanism by which Hrs-2 inhibits endocytosis appears to be similar to that in that it uses exocytosis; Hrs-2 inhibits protein complex formation (Eps15/alpha -adaptin or syntaxin-SNAP-25/VAMP) by competing with one of the complex constituents.

Hrs-2 can regulate both exo- and endocytosis and the process regulated by Hrs-2 at any one time likely depends on the protein machinery with which it is currently interacting. The regulation of these interactions may depend on local calcium concentrations that could switch Hrs-2 from interacting with SNAP-25 to Eps15. Another potential role for Hrs-2 may be in the regulation of Q-SNARE sorting by binding to and excluding SNAP-25 and/or the SNAP-25·syntaxin complex from the endocytic pathway when it is being used for recycling synaptic vesicle membrane and constituent proteins. This would enable sorting of plasma membrane Q-SNAREs away from vesicle constituents following fusion, allowing for segregation of compartmental proteins and membrane composition. Although neuronal cells rely heavily on exo- and endocytosis for synaptic transmission, these processes must be coupled in all eukaryotic cells. Hrs-2 is found in neurons as well as in non-neuronal cells where it interacts with SNAP-23, a SNAP-25 homolog (11). The localization of Hrs-2 on endocytic structures as well as its ability to interact with SNAP-25 (presumably on the plasma membrane) suggests that it may be in a position to regulate both exo- and endocytosis on the membranes involved in these trafficking events. Hrs-2 may act in endocytosis during two stages: an early stage involving coordination through calcium-dependent protein interactions with essential components of both processes and a later stage that is non-Eps15/alpha -adaptin-dependent and involves trafficking of MVBs.

Efficient linkage of the exocytic and endocytic machinery requires that the coupling signal be transient, able to interact with both processes, and able to act at a critical stage in either process. Hrs-2, through its interactions with SNAP-25 and Eps15, may play a regulatory function on the molecular machinery underlying both exo- and endocytosis. The role of Hrs-2 is likely dependent on the local calcium, lipid, and nucleotide microenvironment. The possibility that Hrs-2 toggles between SNAP-25 and Eps15 suggests a mechanism by which this coupling signal may occur.

    Acknowlegments

We thank Drs. PerPalo DiFiore and Lisa Salcini for pCEV and pGEX Eps15 full-length constructs, and Dr. Alexandre Benmerah for Eps15 truncation constructs. We also thank Bill Evans for help throughout these studies, Drs. Sally Kim, Ben Strowbridge, Tom Vida, and Neal Waxham for helpful discussions, and Drs. Vida, Waxham and Vivian Siegel for critical comments on the manuscript.

    FOOTNOTES

* This work was supported in part by the Mallinckrodt Foundation and National Institutes of Health Grant MH058920.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Neurobiology and Anatomy, University of Texas Medical School, 6431 Fannin St., Rm. 7.208, Houston, TX 77030. Tel.: 713-500-5614; Fax: 713-500-0623; E-mail: abean@nba19.med.uth.tmc.edu.

2 A. J. Bean, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: SNAP-25, synaptosomal associated protein of 25 kDa; Eps15, epidermal growth factor receptor substrate 15; VAMP, vesicle-associated membrane protein; Hrs-2, hepatocyte growth factor-regulated tyrosine kinase substrate 2; GST, glutathione S-transferase; PBS-T, phosphate-buffered saline and 0.05% Tween 20; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide electrophoresis; MVB, multivesicular body.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Rothman, J. E. (1994) Nature 372, 55-63[CrossRef][Medline] [Order article via Infotrieve]
2. Scheller, R. H. (1995) Neuron 14, 893-897[CrossRef][Medline] [Order article via Infotrieve]
3. Sudhof, T. C. (1995) Nature 375, 645-653[CrossRef][Medline] [Order article via Infotrieve]
4. Sollner, T., Bennett, M. K., Whiteheart, S. W., Scheller, R. H., and Rothman, J. E. (1993) Cell 75, 409-418[CrossRef][Medline] [Order article via Infotrieve]
5. Oyler, G. A., Higgins, G. A., Hart, R. A., Battenberg, E., Billingsley, M., Bloom, F. E., and Wilson, M. C. (1989) J. Cell Biol. 109, 3039-3052[Abstract/Free Full Text]
6. Chapman, E. R., An, S., Barton, N., and Jahn, R. (1994) J. Biol. Chem. 269, 27427-27432[Abstract/Free Full Text]
7. Fasshauer, D., Eliason, W. K., Brunger, A. T., and Jahn, R. (1998) Biochemistry 37, 10354-10362[CrossRef][Medline] [Order article via Infotrieve]
8. Sutton, R. B., Fasshauer, D., Jahn, R., and Brunger, A. T. (1998) Nature 395, 347-353[CrossRef][Medline] [Order article via Infotrieve]
9. Weber, T., Zemelman, B. V., McNew, J. A., Westermann, B., Gmachl, M., Parlati, F., Sollner, T. H., and Rothman, J. E. (1998) Cell 92, 759-772[CrossRef][Medline] [Order article via Infotrieve]
10. Bean, A. J., Seifert, R., Chen, Y. A., Sacks, R., and Scheller, R. H. (1997) Nature 385, 826-829[CrossRef][Medline] [Order article via Infotrieve]
11. Tsujimoto, S., and Bean, A. J. (2000) J. Biol. Chem 275, 2938-2942[Abstract/Free Full Text]
12. Artalejo, C. R., Henley, J. R., McNiven, M. A., and Palfrey, H. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8328-8332[Abstract/Free Full Text]
13. Burgoyne, R. D. (1995) Pflugers Arch. 430, 213-219[CrossRef][Medline] [Order article via Infotrieve]
14. De Camilli, P., and Takei, K. (1996) Neuron 16, 481-486[CrossRef][Medline] [Order article via Infotrieve]
15. Klingauf, J., Kavalali, E. T., and Tsien, R. W. (1998) Nature 394, 581-585[CrossRef][Medline] [Order article via Infotrieve]
16. Kavalali, E. T., Klingauf, J., and Tsien, R. W. (1999) Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 337-346[Abstract/Free Full Text]
17. Koenig, J. H., and Ikeda, K. (1996) J. Cell Biol. 135, 797-808[Abstract/Free Full Text]
18. Koenig, J. H., Yamaoka, K., and Ikeda, K. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 12677-12682[Abstract/Free Full Text]
19. Koenig, J. H., and Ikeda, K. (1999) J. Neurophys. 81, 1495-1505[Abstract/Free Full Text]
20. Ryan, T. A., Smith, S. J., and Reuter, H. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 5567-5571[Abstract/Free Full Text]
21. Smith, C., and Neher, E. (1997) J. Cell Biol. 139, 885-894[Abstract/Free Full Text]
22. Betz, W. J., and Angleson, J. K. (1998) Annu. Rev. Physiol. 60, 347-363[CrossRef][Medline] [Order article via Infotrieve]
23. Schmid, S. L. (1997) Annu. Rev. Biochem. 66, 511-548[CrossRef][Medline] [Order article via Infotrieve]
24. Hao, W., Luo, Z., Zheng, L., Prasad, K., and Lafer, E. M. (1999) J. Biol. Chem. 274, 22785-22794[Abstract/Free Full Text]
25. Herskovits, J. S., Burgess, C. C., Obar, R. A., and Vallee, R. B. (1993) J. Cell Biol. 122, 565-578[Abstract/Free Full Text]
26. Santini, F., Marks, M. S., and Keen, J. H. (1998) Mol. Biol. Cell 9, 1177-1194[Abstract/Free Full Text]
27. Schmid, S. L., McNiven, M. A., and De Camilli, P. (1998) Curr. Opin. Cell Biol. 10, 504-512[CrossRef][Medline] [Order article via Infotrieve]
28. Sever, S., Muhlberg, A. B., and Schmid, S. L. (1999) Nature 398, 481-486[CrossRef][Medline] [Order article via Infotrieve]
29. Takei, K., Slepnev, V. I., Houcke, V., and De Camilli, P. (1999) Nat. Cell Biol. 1, 33-39[CrossRef][Medline] [Order article via Infotrieve]
30. Wong, W. T., Schumacher, C., Salcini, A. E., Romano, A., Castagnino, P., Pelicci, P. G., and Di Fiore, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9530-9534[Abstract/Free Full Text]
31. Tang, H. Y., Munn, A., and Cai, M. (1997) Mol. Cell. Biol. 17, 4294-4304[Abstract]
32. Paoluzi, S., Castagnoli, L., Lauro, I., Salcini, A. E., Coda, L., Fre, S., Confalonieri, S., Pelicci, P. G., Di Fiore, P. P., and Cesareni, G. (1998) EMBO J. 17, 6541-6550[CrossRef][Medline] [Order article via Infotrieve]
33. Fazioli, F., Minichiello, L., Matoskova, B., Wong, W. T., and Di Fiore, P. P. (1993) Mol. Cell. Biol. 13, 5814-5828[Abstract/Free Full Text]
34. Chen, H., Fre, S., Slepnev, V. I., Capua, M. R., Takei, K., Butler, M. H., Di Fiore, P. P., and De Camilli, P. (1998) Nature 394, 793-797[CrossRef][Medline] [Order article via Infotrieve]
35. Carbone, R., Fre, S., Iannolo, G., Belleudi, F., Mancini, P., Pelicci, P. G., Torrisi, M. R., and Di Fiore, P. P. (1997) Cancer Res. 57, 5498-5504[Abstract/Free Full Text]
36. Salcini, A. E., Confalonieri, S., Doria, M., Santolini, E., Tassi, E., Minenkova, O., Cesareni, G., Pelicci, P. G., and Di Fiore, P. P. (1997) Genes Dev. 11, 2239-2249[Abstract/Free Full Text]
37. Sengar, A. S., Wang, W., Bishay, J., Cohen, S., and Egan, S. E. (1999) EMBO J. 18, 1159-1171[CrossRef][Medline] [Order article via Infotrieve]
38. Torrisi, M. R., Lotti, L. V., Belleudi, F., Gradini, R., Salcini, A. E., Confalonieri, S., Pelicci, P. G., and Di Fiore, P. P. (1999) Mol. Biol. Cell 10, 417-434[Abstract/Free Full Text]
39. Benmerah, A., Lamaze, C., Begue, B., Schmid, S. L., Dautry-Varsat, A., and Cerf-Bensussan, N. (1998) J. Cell Biol. 140, 1055-1062[Abstract/Free Full Text]
40. Wendland, B., and Emr, S. D. (1998) J. Cell Biol. 141, 71-84[Abstract/Free Full Text]
41. Tsujimoto, S., Pelto-Huikko, M., Aitola, M., Meister, B., Vik-Mo, E. O., Davanger, S., Scheller, R. H., and Bean, A. J. (1999) Eur. J. Neurosci. 11, 3047-3063[CrossRef][Medline] [Order article via Infotrieve]
42. Tebar, F., Sorkina, T., Sorkin, A., Ericsson, M., and Kirchhausen, T. (1996) J. Biol. Chem. 271, 28727-28730[Abstract/Free Full Text]
43. Komada, M., Masaki, R., Yamamoto, A., and Kitamura, N. (1997) J. Biol. Chem. 272, 20538-20544[Abstract/Free Full Text]
44. Benmerah, A., Bayrou, M., Cerf-Bensussan, N., and Dautry-Varsat, A. (1999) J. Cell Sci. 112, 1303-1311[Abstract]
45. Cupers, P., ter Haar, E., Boll, W., and Kirchhausen, T. (1997) J. Biol. Chem. 272, 33430-33434[Abstract/Free Full Text]
46. Tebar, F., Confalonieri, S., Carter, R. E., Di Fiore, P. P., and Sorkin, A. (1997) J. Biol. Chem. 272, 15413-15418[Abstract/Free Full Text]
47. Hirst, J., Futter, C. E., and Hopkins, C. R. (1998) Mol. Biol. Cell 9, 809-816[Abstract/Free Full Text]
48. Felder, S., Miller, K., Moehren, G., Ullrich, A., Schlessinger, J., and Hopkins, C. R. (1990) Cell 61, 623-634[CrossRef][Medline] [Order article via Infotrieve]
49. Futter, C. E., Pearse, A., Hewlett, L. J., and Hopkins, C. R. (1996) J. Cell Biol. 132, 1011-1023[Abstract/Free Full Text]
50. Odorizzi, G., Babst, M., and Emr, S. D. (1998) Cell 95, 847-858[CrossRef][Medline] [Order article via Infotrieve]
51. Schmid, S. L., and Smythe, E. (1991) J. Cell Biol. 114, 869-880[Abstract/Free Full Text]


Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. A. Parachoniak and M. Park
Distinct Recruitment of Eps15 via Its Coiled-coil Domain Is Required For Efficient Down-regulation of the Met Receptor Tyrosine Kinase
J. Biol. Chem., March 27, 2009; 284(13): 8382 - 8394.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
I. Roxrud, C. Raiborg, N. M. Pedersen, E. Stang, and H. Stenmark
An endosomally localized isoform of Eps15 interacts with Hrs to mediate degradation of epidermal growth factor receptor
J. Cell Biol., March 24, 2008; 180(6): 1205 - 1218.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
T.-W. Koh, V. I. Korolchuk, Y. P. Wairkar, W. Jiao, E. Evergren, H. Pan, Y. Zhou, K. J.T. Venken, O. Shupliakov, I. M. Robinson, et al.
Eps15 and Dap160 control synaptic vesicle membrane retrieval and synapse development
J. Cell Biol., July 10, 2007; 178(2): 309 - 322.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
F. Bouamr, B. R. Houck-Loomis, M. De Los Santos, R. J. Casaday, M. C. Johnson, and S. P. Goff
The C-Terminal Portion of the Hrs Protein Interacts with Tsg101 and Interferes with Human Immunodeficiency Virus Type 1 Gag Particle Production
J. Virol., March 15, 2007; 81(6): 2909 - 2922.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
Q. Yan, W. Sun, P. Kujala, Y. Lotfi, T. A. Vida, and A. J. Bean
CART: An Hrs/Actinin-4/BERP/Myosin V Protein Complex Required for Efficient Receptor Recycling
Mol. Biol. Cell, May 1, 2005; 16(5): 2470 - 2482.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Kobayashi, N. Tanaka, H. Asao, S. Miura, M. Kyuuma, K. Semura, N. Ishii, and K. Sugamura
Hrs, a Mammalian Master Molecule in Vesicular Transport and Protein Sorting, Suppresses the Degradation of ESCRT Proteins Signal Transducing Adaptor Molecule 1 and 2
J. Biol. Chem., March 18, 2005; 280(11): 10468 - 10477.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
M. Komada and N. Kitamura
The Hrs/STAM Complex in the Downregulation of Receptor Tyrosine Kinases
J. Biochem., January 1, 2005; 137(1): 1 - 8.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. N. Hislop, A. Marley, and M. von Zastrow
Role of Mammalian Vacuolar Protein-sorting Proteins in Endocytic Trafficking of a Non-ubiquitinated G Protein-coupled Receptor to Lysosomes
J. Biol. Chem., May 21, 2004; 279(21): 22522 - 22531.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
E. Mizuno, K. Kawahata, A. Okamoto, N. Kitamura, and M. Komada
Association with Hrs Is Required for the Early Endosomal Localization, Stability, and Function of STAM
J. Biochem., March 1, 2004; 135(3): 385 - 396.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L.-F. Seet, N. Liu, B. J. Hanson, and W. Hong
Endofin Recruits TOM1 to Endosomes
J. Biol. Chem., February 6, 2004; 279(6): 4670 - 4679.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
S. Polo, S. Confalonieri, A. E. Salcini, and P. P. Di Fiore
EH and UIM: Endocytosis and More
Sci. Signal., December 16, 2003; 2003(213): re17 - re17.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. Hinrichsen, J. Harborth, L. Andrees, K. Weber, and E. J. Ungewickell
Effect of Clathrin Heavy Chain- and {alpha}-Adaptin-specific Small Inhibitory RNAs on Endocytic Accessory Proteins and Receptor Trafficking in HeLa Cells
J. Biol. Chem., November 14, 2003; 278(46): 45160 - 45170.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
A. Petiot, J. Faure, H. Stenmark, and J. Gruenberg
PI3P signaling regulates receptor sorting but not transport in the endosomal pathway
J. Cell Biol., September 15, 2003; 162(6): 971 - 979.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
E. Mizuno, K. Kawahata, M. Kato, N. Kitamura, and M. Komada
STAM Proteins Bind Ubiquitinated Proteins on the Early Endosome via the VHS Domain and Ubiquitin-interacting Motif
Mol. Biol. Cell, September 1, 2003; 14(9): 3675 - 3689.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. D. Fisher, B. Wang, S. L. Alam, D. S. Higginson, H. Robinson, W. I. Sundquist, and C. P. Hill
Structure and Ubiquitin Binding of the Ubiquitin-interacting Motif
J. Biol. Chem., August 1, 2003; 278(31): 28976 - 28984.
[Abstract] [Full Text] [PDF]


Home page
JCBHome page
W. Sun, Q. Yan, T. A. Vida, and A. J. Bean
Hrs regulates early endosome fusion by inhibiting formation of an endosomal SNARE complex
J. Cell Biol., July 7, 2003; 162(1): 125 - 137.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Q. Lu, L. W. Hope, M. Brasch, C. Reinhard, and S. N. Cohen
TSG101 interaction with HRS mediates endosomal trafficking and receptor down-regulation
PNAS, June 24, 2003; 100(13): 7626 - 7631.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. G. Bache, C. Raiborg, A. Mehlum, and H. Stenmark
STAM and Hrs Are Subunits of a Multivalent Ubiquitin-binding Complex on Early Endosomes
J. Biol. Chem., March 28, 2003; 278(14): 12513 - 12521.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
D. M. Chetkovich, R. C. Bunn, S.-H. Kuo, Y. Kawasaki, M. Kohwi, and D. S. Bredt
Postsynaptic Targeting of Alternative Postsynaptic Density-95 Isoforms by Distinct Mechanisms
J. Neurosci., August 1, 2002; 22(15): 6415 - 6425.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
R. Heidelberger
ATP Is Required at an Early Step in Compensatory Endocytosis in Synaptic Terminals
J. Neurosci., September 1, 2001; 21(17): 6467 - 6474.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
A. Shukla, H. Hager, T. J. Corydon, A. J. Bean, R. Dahl, Z. Vajda, H. Li, H. J. Hoffmann, and S. Nielsen
SNAP-25-associated Hrs-2 protein colocalizes with AQP2 in rat kidney collecting duct principal cells
Am J Physiol Renal Physiol, September 1, 2001; 281(3): F546 - F556.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bean, A. J.
Right arrow Articles by Chang, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bean, A. J.
Right arrow Articles by Chang, Y.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement